GT200500113A - Derivados de pirimidina para tratar el crecimiento celular anomalo - Google Patents

Derivados de pirimidina para tratar el crecimiento celular anomalo

Info

Publication number
GT200500113A
GT200500113A GT200500113A GT200500113A GT200500113A GT 200500113 A GT200500113 A GT 200500113A GT 200500113 A GT200500113 A GT 200500113A GT 200500113 A GT200500113 A GT 200500113A GT 200500113 A GT200500113 A GT 200500113A
Authority
GT
Guatemala
Prior art keywords
anomalo
treat
cellular growth
derivatives
pirimidine derivatives
Prior art date
Application number
GT200500113A
Other languages
English (en)
Spanish (es)
Inventor
Michael Joseph Luzzio
John Charles Kath
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200500113(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of GT200500113A publication Critical patent/GT200500113A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GT200500113A 2004-05-14 2005-05-13 Derivados de pirimidina para tratar el crecimiento celular anomalo GT200500113A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
GT200500113A true GT200500113A (es) 2006-01-10

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500113A GT200500113A (es) 2004-05-14 2005-05-13 Derivados de pirimidina para tratar el crecimiento celular anomalo

Country Status (27)

Country Link
EP (1) EP1751143A1 (no)
JP (1) JP4099212B2 (no)
KR (1) KR100886990B1 (no)
CN (2) CN102127058A (no)
AP (1) AP2241A (no)
AR (1) AR049097A1 (no)
AU (2) AU2005243397A1 (no)
BR (1) BRPI0511138A (no)
CA (1) CA2566707A1 (no)
CR (1) CR8749A (no)
EA (1) EA200601796A1 (no)
EC (1) ECSP066997A (no)
GE (1) GEP20104875B (no)
GT (1) GT200500113A (no)
IL (1) IL178828A0 (no)
MA (1) MA28583B1 (no)
MX (1) MXPA06011890A (no)
NL (2) NL1029045C2 (no)
NO (1) NO20064576L (no)
NZ (1) NZ550448A (no)
PA (1) PA8632601A1 (no)
PE (1) PE20060240A1 (no)
TN (1) TNSN06370A1 (no)
TW (1) TWI303635B (no)
UY (1) UY28894A1 (no)
WO (1) WO2005111023A1 (no)
ZA (1) ZA200608394B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4812763B2 (ja) * 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ, インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
CA2634646C (en) * 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
JP4782239B2 (ja) * 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
CN101903357A (zh) * 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
EP2300013B1 (en) * 2008-05-21 2017-09-06 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JPWO2014174745A1 (ja) * 2013-04-26 2017-02-23 国立大学法人京都大学 Eg5阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
WO2024140671A1 (zh) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 一种稠三环类衍生物、包含其的药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL379330A1 (pl) * 2002-12-20 2006-08-21 Pfizer Products Inc. Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek

Also Published As

Publication number Publication date
NL1029045A1 (nl) 2005-11-15
BRPI0511138A (pt) 2007-11-27
AU2009238255A1 (en) 2009-12-03
NL1031845A1 (nl) 2006-07-31
TNSN06370A1 (fr) 2008-02-22
TW200539871A (en) 2005-12-16
JP2007537234A (ja) 2007-12-20
AP2241A (en) 2011-06-01
PA8632601A1 (es) 2006-06-02
UY28894A1 (es) 2005-12-30
ECSP066997A (es) 2007-02-28
NL1031845C2 (nl) 2006-11-23
KR100886990B1 (ko) 2009-03-04
TWI303635B (en) 2008-12-01
PE20060240A1 (es) 2006-04-01
NZ550448A (en) 2010-11-26
AU2005243397A1 (en) 2005-11-24
EA200601796A1 (ru) 2007-04-27
IL178828A0 (en) 2007-03-08
ZA200608394B (en) 2008-05-28
CR8749A (es) 2006-12-05
MXPA06011890A (es) 2006-12-14
CN102127058A (zh) 2011-07-20
CA2566707A1 (en) 2005-11-24
KR20070012477A (ko) 2007-01-25
JP4099212B2 (ja) 2008-06-11
GEP20104875B (en) 2010-01-11
WO2005111023A1 (en) 2005-11-24
AR049097A1 (es) 2006-06-28
NL1029045C2 (nl) 2006-06-02
CN1953974A (zh) 2007-04-25
NO20064576L (no) 2006-11-07
EP1751143A1 (en) 2007-02-14
MA28583B1 (fr) 2007-05-02
AP2006003790A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
GT200500113A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
BRPI0513310A (pt) análogos de tetrapeptìdeo
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PA8777101A1 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
HN2006042221A (es) Derivados de piridina para el tratamiento del crecimiento celular anormal
HN2003000422A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
GT200500260A (es) Amidas biciclicas como inhibidores de cinasa.
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
PA8650801A1 (es) Composiciones y formulaciones de ecteinascidina, como la ecteinascidina 743
GT200500237A (es) Derivados de pirimidina
BRPI0416981A (pt) compostos para tratamento de doenças proliferativas de célula
DOP2006000052A (es) Alargar el tiempo hasta la progresión de la enfermedad o la supervivencia de los pacientes de cáncer
HN2011000876A (es) Inhibidores de las enzimas de proteina cinaza activadas por mitogeno p38
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
PA8632701A1 (es) Compuestos terapeuticos
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
CR8288A (es) 6-[ (sustituido) fenil] triazolopirimidinas como agentes anticancer
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CR8574A (es) Compuestos silinano como inhibidores de cisteina proteasa
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
GT200500310A (es) Compuestos organicos
AR052346A1 (es) Composicion que comprende una epotilona y metodos para producir dicha composicion